An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Relation to COVID 19 (DARE 19)

About this Study

To evaluate the effects of dapagliflozin, as compared with placebo, on the risk of death or disease progression in patients hospitalized with COVID-19.

Sponsor Protocol ID:D1690C00081
IRB Number:2020-0115
Closed for Enrollment
Interventional
Phase 3
April 16, 2020
Eligibility Criteria
18 years old
Both Male and Female
No
No
No

Inclusion Criteria(1) >18 years of age; 
(2) Lab-confirmed SARS-CoV-2 infection less than 72 hours prior to randomization or strongly suspected on presentation; 
(3) currently hospitalized; 
(4) Mild-moderate disease (SpO2 ≥ 94% with low-flow supplemental oxygen); 
(5) Medical history of at least one of the following: hypertension, Type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, or CKD stage 3 to 4; and
(6) Chest radiography or CT findings consistent with COVID-19.

Exclusion Criteria(1) Severe COVID-19 (requiring mechanical ventilation and/or non-invasive ventilation or expected need for mechanical ventilation within 24 hours); 
(2) History of type 1 diabetes mellitus or diabetic ketoacidosis; 
(3) eGFR  or receiving renal replacement therapy/dialysis;
(4) Current participation in another interventional clinical trial (with an investigational drug);
(5) Evidence of oliguria or serum creatinine >= 1.5 X baseline pre-hospitalization value;
(6) Systolic blood pressure 
(7) Has received in the last 14 days experimental immune modulators and/or monoclonal antibody therapies for COVID-19;

(8) Treatment with any SGLT2i (e.g., dapagliflozin, canagliflozin, empagliflozin, ertugliflozin) within the previous 4 weeks; and

(9) Pregnancy or breastfeeding.

 

Categories Click category to view its trials.
COVID-19 (Coronavirus)
Participating Locations
University Hospital - UMMC
Contact Information
Contact Name: Savannah Vann
Phone Number: 601-496-7811
Email: svann@umc.edu
Principal Investigator:Garla, Vishnu V, M.D.
How to participate in our Clinical Trials